| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| JAZZJazz Pharmaceuticals plc | 10.4B | 171.16 | 19.79 | 6.12% | -8.86% | -9.31% | 12.96% | 1.51 |
| ACADACADIA Pharmaceuticals Inc. | 4.49B | 26.53 | 19.51 | 31.85% | 24.94% | 28.47% | 3.5% | 0.07 |
| CPRXCatalyst Pharmaceuticals, Inc. | 2.82B | 22.96 | 17.53 | 23.49% | 37.63% | 23.64% | 8.48% | 0.00 |
| HRMYHarmony Biosciences Holdings, Inc. | 2.1B | 36.41 | 14.51 | 22.8% | 22.48% | 22.23% | 10.43% | 0.28 |
| ALKSAlkermes plc | 5.15B | 31.22 | 14.39 | -6.36% | 22.27% | 19.55% | 7.87% | 0.05 |
| PRTCPureTech Health plc | 463.31M | 19.17 | 9.59 | 44.98% | -495.91% | -8.53% | 0.05 | |
| LBRXLB Pharmaceuticals Inc Common Stock | 540.89M | 21.38 | -1.20 | |||||
| NMRANeumora Therapeutics, Inc. Common Stock | 361.97M | 2.13 | -1.39 | -178.79% | 0.01 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 40.3K | 17.33K | 499.89K | 6.04M | 2.76M | 3.61M | 2.92M | 1.42M | 1.61M | 404.1K |
| Revenue Growth % | -0.53% | -0.57% | 27.85% | 11.09% | -0.54% | 0.31% | -0.19% | -0.51% | 0.13% | -0.75% |
| Cost of Goods Sold | 40.3K | 17.33K | 29.76K | 144.17K | 230.1K | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | 1% | 1% | 0.06% | 0.02% | 0.08% | - | - | - | - | - |
| Gross Profit | 0 | 0 | 470.13K | 5.9M | 2.53M | 3.61M | 2.92M | 1.42M | 1.61M | 404.1K |
| Gross Margin % | - | - | 0.94% | 0.98% | 0.92% | 1% | 1% | 1% | 1% | 1% |
| Gross Profit Growth % | - | - | - | 11.55% | -0.57% | 0.43% | -0.19% | -0.51% | 0.13% | -0.75% |
| Operating Expenses | 2.64M | 3.14M | 3.24M | 7.47M | 17.14M | 15.86M | 18.42M | 11.96M | 3.86M | 3.16M |
| OpEx % of Revenue | 65.53% | 181.28% | 6.47% | 1.24% | 6.2% | 4.39% | 6.32% | 8.41% | 2.39% | 7.82% |
| Selling, General & Admin | 1.57M | 1.52M | 2.2M | 4.72M | 4.31M | 5.75M | 7.75M | 3.26M | 2.03M | 1.68M |
| SG&A % of Revenue | 38.9% | 87.85% | 4.39% | 0.78% | 1.56% | 1.59% | 2.66% | 2.29% | 1.26% | 4.15% |
| Research & Development | 761.22K | 819.33K | 841.31K | 2.37M | 12.45M | 10.37M | 9.01M | 7.88M | 942.71K | 435.19K |
| R&D % of Revenue | 18.89% | 47.28% | 1.68% | 0.39% | 4.51% | 2.87% | 3.09% | 5.54% | 0.58% | 1.08% |
| Other Operating Expenses | 311.82K | 799.7K | 197.67K | 382.99K | 374.01K | -266.32K | 1.66M | 817.79K | 882.25K | 1.05M |
| Operating Income | -3.87M | -3.13M | -3.24M | -1.42M | -14.6M | -12.24M | -15.51M | -10.54M | -2.24M | -2.76M |
| Operating Margin % | -95.98% | -180.6% | -6.47% | -0.24% | -5.29% | -3.39% | -5.32% | -7.41% | -1.39% | -6.82% |
| Operating Income Growth % | -1.15% | 0.19% | -0.03% | 0.56% | -9.25% | 0.16% | -0.27% | 0.32% | 0.79% | -0.23% |
| EBITDA | -3.84M | -3.1M | -3.22M | -1.42M | -14.27M | -11.86M | -15.16M | -10.22M | -1.94M | -2.5M |
| EBITDA Margin % | -95.33% | -179.11% | -6.44% | -0.24% | -5.17% | -3.28% | -5.2% | -7.18% | -1.2% | -6.17% |
| EBITDA Growth % | -1.28% | 0.19% | -0.04% | 0.56% | -9.04% | 0.17% | -0.28% | 0.33% | 0.81% | -0.29% |
| D&A (Non-Cash Add-back) | 25.88K | 25.76K | 15.25K | 2.94K | 333.84K | 378.75K | 347.61K | 323.14K | 305.95K | 260.12K |
| EBIT | -3.9M | -3.14M | -3.24M | -1.51M | -14.65M | -12.79M | -15.29M | -10.78M | -2.5M | -4.91M |
| Net Interest Income | -112.35K | -6.9K | 0 | -134.31K | -91.64K | -34.2K | -57.69K | -19.65K | 42.36K | 5.62K |
| Interest Income | 39.86K | 27 | 0 | 85.87K | 36.87K | 35.3K | 5.32K | 29.25K | 63.96K | 9.16K |
| Interest Expense | 152.21K | 6.92K | 45.35K | 220.17K | 128.52K | 69.5K | 63.01K | 48.9K | 21.61K | 3.55K |
| Other Income/Expense | -1.56M | -19.79K | -45.35K | -220.17K | -176.45K | -615.33K | 154K | -263.06K | -257.19K | -2.15M |
| Pretax Income | -4.2M | -3.15M | -3.28M | -1.64M | -14.78M | -12.86M | -15.35M | -10.8M | -2.5M | -4.91M |
| Pretax Margin % | -104.32% | -181.74% | -6.56% | -0.27% | -5.35% | -3.56% | -5.26% | -7.6% | -1.55% | -12.15% |
| Income Tax | 152.21K | 6.92K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1.93% | 4.22% | -1.44% |
| Net Income | -4.2M | -3.15M | -3.28M | -1.64M | -14.78M | -12.86M | -15.35M | -20.8M | -10.56M | 7.06M |
| Net Margin % | -104.32% | -181.74% | -6.56% | -0.27% | -5.35% | -3.56% | -5.26% | -14.63% | -6.54% | 17.46% |
| Net Income Growth % | -1.37% | 0.25% | -0.04% | 0.5% | -7.99% | 0.13% | -0.19% | -0.36% | 0.49% | 1.67% |
| Net Income (Continuing) | -4.2M | -3.15M | -3.28M | -1.64M | -14.78M | -12.86M | -15.35M | -10.8M | -2.5M | -4.91M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -10M | -8.06M | 11.97M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -46.80 | -33.60 | -30.00 | -8.47 | -67.20 | -57.60 | -54.00 | -55.20 | -16.80 | 8.40 |
| EPS Growth % | -1.17% | 0.28% | 0.11% | 0.72% | -6.93% | 0.14% | 0.06% | -0.02% | 0.7% | 1.5% |
| EPS (Basic) | -46.80 | -33.60 | -30.00 | -8.47 | -67.20 | -57.60 | -54.00 | -55.20 | -16.80 | 8.40 |
| Diluted Shares Outstanding | 90.43K | 95.1K | 107.84K | 194.11K | 220.24K | 222.35K | 284.33K | 376.54K | 619.23K | 817.61K |
| Basic Shares Outstanding | 90.43K | 95.1K | 107.84K | 194.11K | 220.24K | 222.35K | 284.33K | 376.54K | 619.23K | 817.61K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 2.78M | 1.66M | 3.05M | 42.15M | 32.39M | 19.49M | 21.94M | 7.83M | 4.23M | 3.54M |
| Cash & Short-Term Investments | 2.63M | 1.42M | 2.59M | 41.68M | 31.55M | 18.76M | 20.5M | 6.96M | 3.87M | 3.35M |
| Cash Only | 2.63M | 1.42M | 2.59M | 41.67M | 31.54M | 18.7M | 20.48M | 6.96M | 3.87M | 3.34M |
| Short-Term Investments | 0 | 0 | 0 | 7.98K | 13.97K | 64.93K | 17.14K | 3.17K | 848 | 6.5K |
| Accounts Receivable | 132.07K | 220.72K | 303.88K | 273.02K | 118.03K | 68.37K | 324.42K | 598.32K | 151.27K | 15.51K |
| Days Sales Outstanding | 1.2K | 4.65K | 221.88 | 16.49 | 15.59 | 6.91 | 40.6 | 153.53 | 34.23 | 14.01 |
| Inventory | 0 | 0 | 0 | 0 | -13.97K | 162.84K | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 13.97K | 0 | 0 | 0 | 0 | 7.97K |
| Total Non-Current Assets | 106.95K | 24.41K | 9.84K | 63.27K | 639.88K | 692.25K | 600.01K | 453.09K | 407.28K | 7.14M |
| Property, Plant & Equipment | 31.84K | 17.3K | 2.75K | 8.87K | 570.97K | 633.1K | 542.1K | 398.73K | 352.94K | 42.71K |
| Fixed Asset Turnover | 1.27x | 1.00x | 181.71x | 681.54x | 4.84x | 5.71x | 5.38x | 3.57x | 4.57x | 9.46x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 75.11K | 7.1K | 7.09K | 54.4K | 0 | 0 | 0 | 0 | 0 | 7.09M |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 68.91K | 59.14K | 57.91K | 54.35K | 54.34K | 7.09K |
| Total Assets | 2.89M | 1.68M | 3.06M | 42.21M | 33.03M | 20.18M | 22.54M | 8.28M | 4.64M | 10.68M |
| Asset Turnover | 0.01x | 0.01x | 0.16x | 0.14x | 0.08x | 0.18x | 0.13x | 0.17x | 0.35x | 0.04x |
| Asset Growth % | -0.28% | -0.42% | 0.82% | 12.78% | -0.22% | -0.39% | 0.12% | -0.63% | -0.44% | 1.3% |
| Total Current Liabilities | 1.03M | 1.25M | 1.48M | 2.33M | 5.68M | 3.62M | 4.13M | 3.28M | 2.89M | 802.09K |
| Accounts Payable | 170.9K | 669.68K | 383.21K | 1.15M | 2.22M | 983.54K | 1.79M | 1.28M | 984.38K | 253.29K |
| Days Payables Outstanding | 1.55K | 14.11K | 4.7K | 2.91K | 3.52K | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 158 | 0 | 439.02K | 212.74K | 1000K | 820.15K | 0 | 0 | 234.98K | 0 |
| Other Current Liabilities | 0 | 0 | 439.02K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Ratio | 2.70x | 1.33x | 2.07x | 18.06x | 5.70x | 5.38x | 5.31x | 2.39x | 1.46x | 4.42x |
| Quick Ratio | 2.70x | 1.33x | 2.07x | 18.06x | 5.70x | 5.34x | 5.31x | 2.39x | 1.46x | 4.42x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 195.66K | 214.44K | 243.86K | 639.35K | 1.82M | 1.95M | 1.48M | 87.03K | 603.14K | 198.94K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 177.22K | 258.79K | 194.32K | 87.03K | 70.38K | 34.69K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 195.66K | 214.44K | 243.86K | 639.35K | 1.65M | 1.69M | 1.28M | 0 | 443.52K | 164.25K |
| Total Liabilities | 1.23M | 1.46M | 1.72M | 2.97M | 7.5M | 5.57M | 5.61M | 3.37M | 3.5M | 1M |
| Total Debt | 0 | 0 | 0 | 0 | 550.25K | 567.4K | 482.01K | 373.13K | 344.34K | 41.99K |
| Net Debt | -2.63M | -1.42M | -2.59M | -41.67M | -30.99M | -18.13M | -20M | -6.58M | -3.52M | -3.3M |
| Debt / Equity | - | - | - | - | 0.02x | 0.04x | 0.03x | 0.08x | 0.30x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -25.41x | -451.99x | -71.34x | -6.47x | -113.64x | -176.16x | -246.08x | -215.57x | -103.81x | -776.78x |
| Total Equity | 1.66M | 218.59K | 1.34M | 39.24M | 25.52M | 14.61M | 16.93M | 4.91M | 1.15M | 9.68M |
| Equity Growth % | -0.29% | -0.87% | 5.14% | 28.23% | -0.35% | -0.43% | 0.16% | -0.71% | -0.77% | 7.45% |
| Book Value per Share | 18.40 | 2.30 | 12.45 | 202.16 | 115.89 | 65.71 | 59.55 | 13.05 | 1.85 | 11.84 |
| Total Shareholders' Equity | 1.66M | 218.59K | 1.34M | 39.24M | 25.52M | 14.61M | 16.93M | 4.91M | 1.15M | 9.68M |
| Common Stock | 11.03M | 11.56M | 13.42M | 28.56M | 32.85M | 32.85M | 49.27M | 1.15M | 1.84M | 1.84M |
| Retained Earnings | -277.99M | -281.14M | -284.42M | -286.07M | -300.85M | -313.71M | -329.06M | -349.86M | -360.42M | -353.36M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | -6.08M | -11.7M | -6.28M | -909.57K | -869.71K |
| Accumulated OCI | 6.55M | 6.76M | 7.55M | 10.27M | 7.15M | 14.66M | 24.44M | 25.77M | 29.81M | 31.06M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -2.63M | -2.69M | -2.13M | 1.75M | -9.48M | -12.18M | -14.71M | -16.44M | -7.99M | -5.37M |
| Operating CF Margin % | -65.22% | -155.48% | -4.27% | 0.29% | -3.43% | -3.37% | -5.04% | -11.56% | -4.96% | -13.3% |
| Operating CF Growth % | -0.46% | -0.03% | 0.21% | 1.82% | -6.41% | -0.28% | -0.21% | -0.12% | 0.51% | 0.33% |
| Net Income | -4.2M | -3.15M | -3.28M | -1.64M | -14.78M | -12.86M | -15.35M | -20.8M | -10.56M | 7.06M |
| Depreciation & Amortization | 25.88K | 25.76K | 15.25K | 2.94K | 333.84K | 378.75K | 347.61K | 323.14K | 305.95K | 260.12K |
| Stock-Based Compensation | 355.91K | 197.35K | 800.19K | 2.3M | 1.69M | 1.18M | 1.18M | 3.68M | 1.79M | 0 |
| Deferred Taxes | 863.46K | 17.82K | 19.52K | 20.01K | 96.53K | -27.72K | -150.59K | 0 | 0 | 0 |
| Other Non-Cash Items | 336.27K | 19.79K | 45.35K | 331.93K | 523.88K | 972.63K | 32.93K | 204.13K | 249.64K | -11.46M |
| Working Capital Changes | -5.75K | 194.28K | 265.15K | 742.72K | 2.66M | -1.82M | -761.57K | 157.68K | 213.76K | -1.23M |
| Change in Receivables | 0 | 0 | -83.16K | 30.87K | 154.99K | 49.66K | -96.41K | -252.09K | 306.51K | 134.01K |
| Change in Inventory | 0 | 0 | 0 | 0 | -2.12M | 1.54M | -883.84K | 427.39K | 0 | 0 |
| Change in Payables | 0 | 0 | -212.13K | 1.08M | 1.97M | -1.59M | 883.84K | -427.39K | 0 | 0 |
| Cash from Investing | 399.9K | -1.51K | -697 | -61.74K | -43.25K | -59.41K | -30.31K | 2.97K | -6.84K | 4.65M |
| Capital Expenditures | 0 | -11.22K | -697 | -9.05K | -28.46K | -59.41K | -31.55K | -581 | -6.84K | -1.27K |
| CapEx % of Revenue | - | 0.65% | 0% | 0% | 0.01% | 0.02% | 0.01% | 0% | 0% | 0% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 399.9K | 9.71K | 0 | -5.37K | 0 | 0 | 0 | 0 | 0 | 5.12M |
| Cash from Financing | 2.93M | 1.49M | 3.36M | 37.39M | -463.69K | 46.4K | 16.4M | 3.1M | 5.26M | 104.92K |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | -253.7K | -32.32K | -25.74K | -3.1M | -152.89K | -306.2K | 2.75M | 1.71M | 3.2M | -62.29K |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -2.63M | -2.71M | -2.14M | 1.74M | -9.51M | -12.24M | -14.74M | -16.44M | -8M | -5.37M |
| FCF Margin % | -65.22% | -156.13% | -4.27% | 0.29% | -3.44% | -3.39% | -5.05% | -11.56% | -4.96% | -13.3% |
| FCF Growth % | -0.46% | -0.03% | 0.21% | 1.82% | -6.46% | -0.29% | -0.2% | -0.12% | 0.51% | 0.33% |
| FCF per Share | -29.07 | -28.45 | -19.80 | 8.98 | -43.18 | -55.05 | -51.83 | -43.65 | -12.92 | -6.57 |
| FCF Conversion (FCF/Net Income) | 0.63x | 0.86x | 0.65x | -1.07x | 0.64x | 0.95x | 0.96x | 0.79x | 0.76x | -0.76x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -209.69% | -334.54% | -420.26% | -8.11% | -45.64% | -64.08% | -97.35% | -190.48% | -348.48% | 130.39% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | - | - | -103.27% |
| Gross Margin | - | - | 94.05% | 97.61% | 91.67% | 100% | 100% | 100% | 100% | 100% |
| Net Margin | -10432.03% | -18174.08% | -656.22% | -27.21% | -534.98% | -355.92% | -526.42% | -1462.57% | -654.47% | 1746.04% |
| Debt / Equity | - | - | - | - | 0.02x | 0.04x | 0.03x | 0.08x | 0.30x | 0.00x |
| Interest Coverage | -25.41x | -451.99x | -71.34x | -6.47x | -113.64x | -176.16x | -246.08x | -215.57x | -103.81x | -776.78x |
| FCF Conversion | 0.63x | 0.86x | 0.65x | -1.07x | 0.64x | 0.95x | 0.96x | 0.79x | 0.76x | -0.76x |
| Revenue Growth | -52.81% | -57% | 2784.72% | 1109.03% | -54.29% | 30.77% | -19.28% | -51.22% | 13.39% | -74.95% |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Research | - | - | 2.9M | 1.4M | 1.6M | 400K |
| Research Growth | - | - | - | -51.72% | 14.29% | -75.00% |
| Ifrs Research | 2.8M | 3.6M | - | - | - | - |
| Ifrs Research Growth | - | 28.57% | - | - | - | - |
Addex Therapeutics Ltd (ADXN) has a price-to-earnings (P/E) ratio of 1.0x. This may indicate the stock is undervalued or faces growth challenges.
Addex Therapeutics Ltd (ADXN) reported $0.1M in revenue for fiscal year 2024. This represents a 97% decrease from $2.8M in 2011.
Addex Therapeutics Ltd (ADXN) saw revenue decline by 74.9% over the past year.
Addex Therapeutics Ltd (ADXN) reported a net loss of $6.0M for fiscal year 2024.
Addex Therapeutics Ltd (ADXN) has a return on equity (ROE) of 130.4%. This is excellent, indicating efficient use of shareholder capital.
Addex Therapeutics Ltd (ADXN) had negative free cash flow of $1.4M in fiscal year 2024, likely due to heavy capital investments.